Related Experiment Video
Updated: Jun 11, 2026
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Defining a CMV viral load threshold for pre-emptive therapy in paediatric haematopoietic stem cell transplant
Amedine Duret1, Oscar Charles2, Ben K Margetts2,3,4
1Department of Paediatric Infectious Diseases, Imperial College London, London, UK.
Insights
A new threshold of 1000 IU/mL for Cytomegalovirus (CMV) viral load is recommended for pre-emptive treatment in pediatric hematopoietic stem cell transplant (HSCT) patients. This evidence-based approach significantly reduces CMV disease and mortality.
Area of Science:
- Pediatric Hematology
- Infectious Diseases
- Transplantation Immunology
Background:
- Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in pediatric hematopoietic stem cell transplant (HSCT) recipients.
- Current pre-emptive treatment protocols for CMV in children are often based on adult data, lacking specific validation for pediatric populations.
Purpose of the Study:
- To determine an optimal viral load threshold for initiating pre-emptive CMV therapy in pediatric HSCT patients.
- To evaluate the clinical impact of implementing a revised, evidence-based CMV treatment threshold.
Main Methods:
- A prospective interventional study analyzed CMV kinetics, morbidity, and mortality in pediatric HSCT patients.
- A mathematical model suggested a 1000 IU/mL threshold, which was then implemented in a second cohort.
- CMV quantitative polymerase chain reaction (qPCR) monitoring was used weekly.
Main Results:
- Implementation of the 1000 IU/mL threshold led to significant reductions in CMV viral loads.
- CMV-associated end-organ disease decreased from 23.1% to 4.1%.
- Mortality rates decreased from 30.8% to 19.4% in the cohort treated with the new threshold.
Conclusions:
- An evidence-based viral load threshold of 1000 IU/mL or less is recommended for initiating pre-emptive CMV treatment in pediatric HSCT recipients.
- This revised threshold optimizes clinical outcomes by reducing CMV-related complications and mortality.
- The study provides a validated, pediatric-specific approach to CMV management post-HSCT.
Abstract:
Cytomegalovirus (CMV) infection is a significant complication in paediatric haematopoietic stem cell transplant (HSCT), with substantial morbidity and mortality. While pre-emptive treatment guided by CMV viral load thresholds helps prevent end-organ disease, paediatric protocols have largely been extrapolated from adult populations without robust validation. This prospective interventional study aimed to determine an optimal viral load threshold for initiating pre-emptive CMV therapy in paediatric HSCT patients and test the impact of this threshold in real-world practice. Initially, 219 paediatric HSCT patients from 2009 to 2016 were considered, with weekly CMV quantitative polymerase chain reaction (qPCR) monitoring and treatment initiation at 2500 IU/mL. A mathematical model was developed to analyse CMV kinetics, morbidity and mortality, suggesting a threshold of 1000 IU/mL would be most suitable to prevent adverse outcomes. Subsequently, the new treatment threshold was implemented, and outcomes were then compared with a second cohort of 344 patients treated under the new guidelines from 2017 to 2021. There were significant reductions in CMV viral loads, CMV-associated end-organ disease (27/117, 23.1% vs. 4/98, 4.1%) and mortality (36/117, 30.8% vs. 19/98, 19.4%). These findings support a new evidence-based viral load threshold of 1000 IU/mL or less for pre-emptive treatment in paediatric HSCT recipients to optimise clinical outcomes.
More Related Videos
11:18Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
